Latest Sphingosine-1-phosphate Stories
Conference Call Scheduled for Today at 4:30 p.m. ET to Provide Investor Update SAN DIEGO, March 24, 2015 /PRNewswire/ -- Lpath, Inc.
- Trial results show novel S1P1 modulator produced strong, dose-dependent lymphocyte lowering - SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Lpath, Inc.
Patent Provides Coverage for Lpath's Anti-S1P Antibody in Europe SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Lpath, Inc.
SAN DIEGO, June 3, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
Lpath will also host an investor call and webcast on Wednesday, June 4, 2014 at 4:30 p.m.
SBIR Grant from the National Institutes of Neurological Diseases and Stroke Provides Funds for IND-enabling Studies of Lpathomab SAN DIEGO, May 5, 2014 /PRNewswire/ -- Lpath, Inc.
Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan.
A trace substance in caramelized sugar, when purified and given in appropriate doses, improves muscle regeneration in a mouse model of Duchenne muscular dystrophy.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.